AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9198795 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 7967322 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate, 10 mg (ID)
Number of subjects: 15
Study 7967322 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine, 20 mg (N)
Number of subjects: 15
Study 7967322 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol, 40 mg (P)
Number of subjects: 15
Study 7967322 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ID, 10 mg + P, 40 mg
Number of subjects: 15
Study 7967322 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of N, 20 mg + P, 40 mg
Number of subjects: 15
Study 7967322 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ID, 10 mg + N, 20 mg
Number of subjects: 15
Study 7967322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3514491 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (time-release preparation)
Number of subjects: 20
Study 3514491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31242300 — intervention group
Group type: EXPERIMENTAL
Intervention: fIPV, 0.1 mL im
Number of subjects: 196
Study 31242300 — intervention group
Group type: EXPERIMENTAL
Intervention: fIPV, 0.2 mL im
Number of subjects: 196
Study 31242300 — intervention group
Group type: EXPERIMENTAL
Intervention: fIPV, 0.1 mL id
Number of subjects: 196
Study 31242300 — intervention group
Group type: COMPARATOR
Intervention: IPV, 0.5 mL im
Number of subjects: 196
Study 29440159 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip arthroscopy with capsular closure
Number of subjects: 200
Study 29440159 — intervention group
Group type: COMPARATOR
Intervention: Hip arthroscopy without capsular closure
Number of subjects: 200
Study 27142077 — intervention group
Group type: EXPERIMENTAL
Intervention: Early potent, largely type I interferon-mediated response
Number of subjects: 115
Study 27142077 — intervention group
Group type: COMPARATOR
Intervention: Modest type I interferon response
Number of subjects: 115
Study 27142077 — intervention group
Group type: COMPARATOR
Intervention: Protracted cytokine response after seroconversion
Number of subjects: 115
Study 23709329 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-G microincision vitrectomy surgery (MIVS)
Number of subjects: 50
Study 23709329 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-G microincision vitrectomy surgery (MIVS)
Number of subjects: 50
Study 23709329 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 23-G and 25-G MIVS
Number of subjects: 50
Study 23186329 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening + Assessment
Number of subjects: 0
Study 23186329 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening + Assessment + Brief Intervention
Number of subjects: 0
Study 23186329 — intervention group
Group type: COMPARATOR
Intervention: Minimal Screening Only
Number of subjects: 0
Study 20222003 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (E)
Number of subjects: 79
Study 20222003 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (S)
Number of subjects: 79
Study 20222003 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (SE)
Number of subjects: 79
Study 20222003 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 79
Study 18678294 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg/day
Number of subjects: 151
Study 18678294 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aspirin 100 mg/day plus clopidogrel 75 mg/day
Number of subjects: 151
Study 15971716 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12759722 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 96
Study 12759722 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 96
Study 12759722 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Quinapril and Atenolol
Number of subjects: 96
Study 11232513 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Care (KC)
Number of subjects: 29
Study 11232513 — intervention group
Group type: COMPARATOR
Intervention: Incubator (Control)
Number of subjects: 29
Study 9493476 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 to 200 mg/day for 10 to 20 days)
Number of subjects: 3
Study 9493476 — intervention group
Group type: COMPARATOR
Intervention: CYP3A substrates (alprazolam, carbamazepine, terfenadine)
Number of subjects: 3
Study 8177920 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (active drug)
Number of subjects: 12
Study 3530364 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole for 10 days
Number of subjects: 162
Study 3530364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 31599955 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-enriched donor milk (≥120 mL·kg‐1·d‐1)
Number of subjects: 158
Study 31599955 — intervention group
Group type: COMPARATOR
Intervention: Preterm formula
Number of subjects: 158
Study 31599955 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital mother's milk intake
Number of subjects: 158
Study 29914380 — intervention group
Group type: EXPERIMENTAL
Intervention: VASP-guided clopidogrel maintenance therapy titrated by platelet reactivity index (PRI)
Number of subjects: 503
Study 29914380 — intervention group
Group type: COMPARATOR
Intervention: Control group with fixed clopidogrel maintenance dose of 75 mg per day
Number of subjects: 503
Study 29914380 — intervention group
Group type: EXPERIMENTAL
Intervention: VASP-guided clopidogrel maintenance therapy
Number of subjects: 503
Study 29914380 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 503
Study 28366170 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of ciprofloxacin 500 mg orally twice daily
Number of subjects: 200
Study 28366170 — intervention group
Group type: COMPARATOR
Intervention: 14 days of ciprofloxacin 500 mg orally twice daily
Number of subjects: 200
Study 26181766 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE) for 3 months (n = 30)
Number of subjects: 81
Study 26181766 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE) for 3 months (n = 27)
Number of subjects: 81
Study 26181766 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 24)
Number of subjects: 81
Study 24189336 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination gait training (robot-assisted treadmill training followed by conventional body-weight-supported treadmill training)
Number of subjects: 7
Study 20482934 — intervention group
Group type: EXPERIMENTAL
Intervention: neurocognitive training
Number of subjects: 116
Study 20482934 — intervention group
Group type: COMPARATOR
Intervention: control condition
Number of subjects: 116
Study 18319635 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction program (n=36)
Number of subjects: 48
Study 18319635 — intervention group
Group type: COMPARATOR
Intervention: Healthy diet weight maintenance control (1 group)
Number of subjects: 48
Study 16800988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganbi decoction (GBD)
Number of subjects: 128
Study 16800988 — intervention group
Group type: COMPARATOR
Intervention: Glucuronolactone tablets and inosine injection (Control)
Number of subjects: 128
Study 16800988 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 128
Study 14665354 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of oral rofecoxib
Number of subjects: 56
Study 14665354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 10435202 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 10435202 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 10435202 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening on the PANSS depression cluster
Number of subjects: 0
Study 9084325 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% CHX gel in gel trays on two consecutive days, followed by application of a fluoride varnish (Group A)
Number of subjects: 24
Study 9084325 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% CHX gel (Group B)
Number of subjects: 24
Study 9084325 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 24
Study 1679047 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol (200 mg twice daily)
Number of subjects: 51
Study 1679047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 1679047 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 51
Study 7104176 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg daily
Number of subjects: 9
Study 7104176 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg daily
Number of subjects: 9
Study 7104176 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamterene 100 mg daily
Number of subjects: 9
Study 7104176 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamterene 200 mg daily
Number of subjects: 9
Study 7104176 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride 32 mmol daily
Number of subjects: 9
Study 7104176 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride 64 mmol daily
Number of subjects: 9
Study 7104176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31434037 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 100 mcg
Number of subjects: 11
Study 31434037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 27940287 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium 44 μg
Number of subjects: 152
Study 27940287 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 18 μg
Number of subjects: 152
Study 25501868 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 50 mg QD for 3 days
Number of subjects: 40
Study 25501868 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 10 mg QD for 3 days
Number of subjects: 40
Study 25501868 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg on Day 3
Number of subjects: 40
Study 25501868 — intervention group
Group type: COMPARATOR
Intervention: Matched apixaban placebo QD for 3 days
Number of subjects: 40
Study 24493300 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride (25 µg or 50 µg twice daily for 9 weeks)
Number of subjects: 120
Study 24493300 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules for 9 weeks
Number of subjects: 120
Study 24493300 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 120
Study 22806348 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-lowering drugs (non-insulin)
Number of subjects: 0
Study 22806348 — intervention group
Group type: COMPARATOR
Intervention: Neurotoxic ART
Number of subjects: 0
Study 22806348 — intervention group
Group type: COMPARATOR
Intervention: Having APN
Number of subjects: 0
Study 19241310 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (80 mg/day, n = 23)
Number of subjects: 46
Study 19241310 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 23)
Number of subjects: 46
Study 17335328 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone (300-600 mg/day, flexible dose)
Number of subjects: 105
Study 17335328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 17335328 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 105
Study 15467559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-anal electromyographic biofeedback
Number of subjects: 60
Study 15467559 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation of the anal sphincter
Number of subjects: 60
Study 12120116 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening colonoscopy
Number of subjects: 0
Study 12120116 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines endorsement
Number of subjects: 0
Study 9672928 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal/Epidural analgesia
Number of subjects: 26
Study 9672928 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 26
Study 9672928 — intervention group
Group type: COMPARATOR
Intervention: Opioid analgesia with fentanyl
Number of subjects: 26
Study 7561468 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 per cent ephedrine hydrochloride nasal drops
Number of subjects: 97
Study 7561468 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone sodium phosphate (Betnosol) nose drops
Number of subjects: 97
Study 7561468 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline nasal douches
Number of subjects: 97
Study 7561468 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nasal medication)
Number of subjects: 97
Study 2228922 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 48
Study 2228922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 461366 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprin and Prednisone
Number of subjects: 0
Study 461366 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Penicillamine and Prednisone
Number of subjects: 0
Study 31870433 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic RCTs
Number of subjects: 45
Study 27230119 — intervention group
Group type: EXPERIMENTAL
Intervention: School adjustment program for middle school transition
Number of subjects: 1147
Study 27230119 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1147
Study 26559255 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic Acid 0.4 mg/day (low-FA)
Number of subjects: 450
Study 26559255 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic Acid 0.8 mg/day (high-FA)
Number of subjects: 450
Study 26559255 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 450
Study 25236946 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric bupivacaine 3.75 mg (B0.25 group)
Number of subjects: 64
Study 25236946 — intervention group
Group type: COMPARATOR
Intervention: Hypobaric bupivacaine 7.5 mg (B0.5 group)
Number of subjects: 64
Study 22114872 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (500 mg capsules, once daily for 14 days)
Number of subjects: 16
Study 20634634 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum
Number of subjects: 76
Study 17196713 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid schedule (Group R, vaccination on days 0, 7 and 21)
Number of subjects: 398
Study 17196713 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated conventional schedule (Group A, vaccination on days 0, 14 and 300)
Number of subjects: 398
Study 17196713 — intervention group
Group type: COMPARATOR
Intervention: Conventional schedule (Group C, vaccination on days 0, 28 and 300)
Number of subjects: 398
Study 17196713 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified conventional schedule (Group M, vaccination on days 0, 21 and 300)
Number of subjects: 398
Study 17196713 — intervention group
Group type: EXPERIMENTAL
Intervention: Group R and Group C
Number of subjects: 398
Study 15572425 — intervention group
Group type: EXPERIMENTAL
Intervention: KBC 30 mmol/d
Number of subjects: 170
Study 15572425 — intervention group
Group type: EXPERIMENTAL
Intervention: KBC 60 mmol/d
Number of subjects: 170
Study 15572425 — intervention group
Group type: EXPERIMENTAL
Intervention: KBC 90 mmol/d
Number of subjects: 170
Study 15572425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 12081581 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.6 g/kg/day)
Number of subjects: 82
Study 12081581 — intervention group
Group type: COMPARATOR
Intervention: Usual-protein diet (1.02 g/kg/day)
Number of subjects: 82
Study 10360856 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 alone
Number of subjects: 8
Study 10360856 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane alone
Number of subjects: 8
Study 10360856 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane plus IL-2
Number of subjects: 8
Study 10360856 — intervention group
Group type: COMPARATOR
Intervention: Control (no desflurane, no IL-2)
Number of subjects: 8
Study 9638216 — intervention group
Group type: EXPERIMENTAL
Intervention: Apranax 550
Number of subjects: 60
Study 9638216 — intervention group
Group type: COMPARATOR
Intervention: Voltaren 50
Number of subjects: 60
Study 2778693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocufen (flurbiprofen) drops
Number of subjects: 100
Study 2778693 — intervention group
Group type: COMPARATOR
Intervention: Standard dilating regimen (Control)
Number of subjects: 100
Study 16794 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 30
Study 16794 — intervention group
Group type: EXPERIMENTAL
Intervention: Noxiptyline
Number of subjects: 30
Study 16794 — intervention group
Group type: EXPERIMENTAL
Intervention: Dibenzepine
Number of subjects: 30
Study 16794 — intervention group
Group type: COMPARATOR
Intervention: Hamilton Rating Scale for depression
Number of subjects: 30
Study 16794 — intervention group
Group type: COMPARATOR
Intervention: Hildreth Feeling Scale
Number of subjects: 30
Study 16794 — intervention group
Group type: COMPARATOR
Intervention: D Scale
Number of subjects: 30
Study 16794 — intervention group
Group type: COMPARATOR
Intervention: Trail Making Test
Number of subjects: 30
Study 31507061 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-based screening (PS)
Number of subjects: 1034
Study 31507061 — intervention group
Group type: COMPARATOR
Intervention: Family-history (FH) testing
Number of subjects: 1034
Study 31507061 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PS and FH groups
Number of subjects: 1034
Study 31382835 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein water-soluble formulation
Number of subjects: 8
Study 31382835 — intervention group
Group type: COMPARATOR
Intervention: Lutein oil suspension
Number of subjects: 8
Study 28755807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol lowering treatment (simvastatin 40 mg/day, ezetimibe/simvastatin 10/20 mg/day, ezetimibe/simvastatin 10/40 mg/day)
Number of subjects: 30
Study 28755807 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment ezetimibe/simvastatin 10/40 mg/day
Number of subjects: 30
Study 28755807 — intervention group
Group type: COMPARATOR
Intervention: CKD patients
Number of subjects: 30
Study 28755807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol lowering treatment
Number of subjects: 30
Study 26887212 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy combined with diet control and physical exercise
Number of subjects: 60
Study 26887212 — intervention group
Group type: COMPARATOR
Intervention: Control group with diet control and physical exercise
Number of subjects: 60
Study 22622437 — intervention group
Group type: EXPERIMENTAL
Intervention: High anxiety condition during target-directed aiming tasks
Number of subjects: 0
Study 22622437 — intervention group
Group type: COMPARATOR
Intervention: Low anxiety condition during target-directed aiming tasks
Number of subjects: 0
Study 21209230 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosaprepitant 150 mg with oral dexamethasone (8 mg daily for 3 days)
Number of subjects: 23
Study 21209230 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosaprepitant 150 mg with oral midazolam (2 mg on days 1 and 4)
Number of subjects: 23
Study 19737403 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Stepped Care (CSC)
Number of subjects: 134
Study 19737403 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 134
Study 16288313 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome wide linkage study
Number of subjects: 71
Study 15324352 — intervention group
Group type: EXPERIMENTAL
Intervention: Sc/Rp + doxycycline polymer
Number of subjects: 15
Study 15324352 — intervention group
Group type: COMPARATOR
Intervention: Sc/Rp alone
Number of subjects: 15
Study 11605086 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 20 mg
Number of subjects: 0
Study 11605086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9255221 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor I (IGF-I)
Number of subjects: 0
Study 7839427 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome) 1 mg/kg/day for 5 days
Number of subjects: 86
Study 7839427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 7839427 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome)
Number of subjects: 86
Study 2512181 — intervention group
Group type: COMPARATOR
Intervention: hMG alone
Number of subjects: 27
Study 2512181 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG with leuprolide (GnRH-a)
Number of subjects: 27
Study 31010491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐coupled Intensive Balance Training (CIBT) program
Number of subjects: 0
Study 31952661 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy
Number of subjects: 0
Study 31952661 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study 31952661 — intervention group
Group type: EXPERIMENTAL
Intervention: New systemic and surgical treatments
Number of subjects: 0
Study 26330419 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb bioresorbable vascular scaffolds (BVSs)
Number of subjects: 400
Study 26330419 — intervention group
Group type: COMPARATOR
Intervention: Cobalt-chromium everolimus-eluting stents (CoCr-EESs)
Number of subjects: 400
Study 24308189 — intervention group
Group type: EXPERIMENTAL
Intervention: EA plus sitting training
Number of subjects: 120
Study 24308189 — intervention group
Group type: COMPARATOR
Intervention: Sitting training (control)
Number of subjects: 120
Study 21668564 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular atrioventricular (AV) sequential pacing at 100 bpm for 30 minutes
Number of subjects: 22
Study 21668564 — intervention group
Group type: COMPARATOR
Intervention: Irregular atrioventricular (AV) sequential pacing at 100 bpm for 30 minutes
Number of subjects: 22
Study 19332193 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2201